James Barry, Executive Vice President and President of the Life Science Group at Bio-Rad Laboratories, Inc., filed a Form 4 on September 3, 2026, reporting restricted stock unit vestings and a related share withholding transaction dated September 1, 2026.

Key Highlights

  • RSU vesting: 425 shares of Bio-Rad Class A Common Stock were acquired on September 1, 2026, via the vesting of restricted stock units, at a price of $0.
  • Tax withholding disposal: 154 shares were disposed of on September 1, 2026, at $380.96 per share, coded as an "F" (payment of exercise price or tax liability) transaction.
  • Post-transaction holdings: Barry directly owns 780.682 shares of Bio-Rad Class A Common Stock following the reported transactions.
  • Remaining RSUs: 251 restricted stock units remain outstanding following the reported transactions, held directly.
  • 2022 grant details: On September 1, 2022, Barry was granted 694 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
  • 2023 grant details: On September 1, 2023, Barry was granted 1,002 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Bio-Rad Laboratories EVP Reports RSU Vestings and Share Withholding in September 2026

According to the filing, James Barry, identified as EVP and President of the Life Science Group (LSG) at Bio-Rad Laboratories, Inc. (NYSE:BIO, NYSE:BIO.B), reported two transactions in Bio-Rad Class A Common Stock on September 1, 2026. First, 425 shares were acquired through the vesting of restricted stock units at a price of $0, reflecting a conversion of equity awards rather than an open-market purchase. Second, 154 shares were disposed of at $380.96 per share under transaction code "F," which the filing form designates as a disposition for the payment of an exercise price or tax liability.

The filing also reports activity in Table II covering derivative securities. Two tranches of restricted stock units vested on September 1, 2026: 174 units from a September 1, 2022 grant of 694 total RSUs, and 251 units from a September 1, 2023 grant of 1,002 total RSUs. Each restricted stock unit, according to the filing, "represents a contingent right to receive one share of Bio-Rad Class A common stock." Following the reported transactions, zero RSUs from the 2022 grant and 251 RSUs from the 2023 grant remain outstanding, all held directly.

After all reported transactions, Barry's direct beneficial ownership in Bio-Rad Class A Common Stock stands at 780.682 shares, as reported in the filing. The Form 4 was signed by James Barry on September 2, 2026, and filed on September 3, 2026.

What Was Disclosed

The filing discloses two RSU tranche vestings totaling 425 shares acquired at $0, a disposal of 154 shares at $380.96 for tax withholding purposes, and a resulting direct beneficial ownership of 780.682 shares of Bio-Rad Class A Common Stock, with 251 RSUs remaining outstanding.